DWP
UTHR icon

Daymark Wealth Partners’s United Therapeutics UTHR Stock Holding History

Daymark Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$305K Sell
563
-6
-1% -$3.38K 0.01% 628
2026
Q1 		$337K Buy
+569
New +$283K 0.01% 538

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Daymark Wealth Partners's UTHR Position: Q2 2026 in Review

Daymark Wealth Partners reduced its United Therapeutics (UTHR) stake by 1.1% in Q2 2026, selling an estimated $3.38K and leaving 563 shares worth $305K. The position accounts for 0.01% of the portfolio, ranked #628.

Daymark Wealth Partners first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. The position peaked at $337K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Daymark Wealth Partners held 563 shares of United Therapeutics worth $305K as of Q2 2026.
  • Daymark Wealth Partners sold 6 United Therapeutics shares in Q2 2026, an estimated $3.38K.
  • United Therapeutics made up 0.01% of Daymark Wealth Partners's portfolio in Q2 2026, its #628 holding.
  • Daymark Wealth Partners first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Daymark Wealth Partners's United Therapeutics position peaked at $337K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.